Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiuweihuaban Pill in Plaque Psoriasis
NCT06058546Phase 2Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Jiuweihuaban Pill in plaque psoriasis (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Proportion of subjects achieving PASI 75 at 84 days. Started Nov 2023; status: recruiting.
02
Drugs
Jiuweihuaban Pill
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06058546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058546.